261 related articles for article (PubMed ID: 18511895)
21. A new challenge for Europe: introducing a pediatric quadrivalent vaccine for measles, mumps, rubella, and varicella.
Ramet J
Int J Infect Dis; 2007 Nov; 11 Suppl 2():S49-55. PubMed ID: 18162247
[TBL] [Abstract][Full Text] [Related]
22. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and safety of immunization with live-attenuated and inactivated vaccines for pediatric liver transplantation recipients.
Kawano Y; Suzuki M; Kawada J; Kimura H; Kamei H; Ohnishi Y; Ono Y; Uchida H; Ogura Y; Ito Y
Vaccine; 2015 Mar; 33(12):1440-5. PubMed ID: 25665961
[TBL] [Abstract][Full Text] [Related]
24. A combination vaccine against measles, mumps, rubella and varicella.
Knuf M; Faber J; Barth I; Habermehl P
Drugs Today (Barc); 2008 Apr; 44(4):279-92. PubMed ID: 18536786
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial.
Lalwani S; Chatterjee S; Balasubramanian S; Bavdekar A; Mehta S; Datta S; Povey M; Henry O
BMJ Open; 2015 Sep; 5(9):e007202. PubMed ID: 26362659
[TBL] [Abstract][Full Text] [Related]
26. Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age.
Stück B; Stehr K; Bock HL
Asian Pac J Allergy Immunol; 2002 Jun; 20(2):113-20. PubMed ID: 12403196
[TBL] [Abstract][Full Text] [Related]
27. A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process.
Marshall GS; Senders SD; Shepard J; Twiggs JD; Gardner J; Hille D; Hartzel J; Valenzuela R; Stek JE; Helmond FA
Hum Vaccin Immunother; 2016 Aug; 12(8):2188-2196. PubMed ID: 27149048
[TBL] [Abstract][Full Text] [Related]
28. The evolution of vaccines for early childhood: the MMRV.
Ferrera G; Squeri R; Genovese C
Ann Ig; 2018; 30(4 Supple 1):33-37. PubMed ID: 30062378
[TBL] [Abstract][Full Text] [Related]
29. Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine.
Vesikari T; Sadzot-Delvaux C; Rentier B; Gershon A
Pediatr Infect Dis J; 2007 Jul; 26(7):632-8. PubMed ID: 17596807
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity and safety of intramuscular versus subcutaneous administration of a combined measles, mumps, rubella, and varicella vaccine to children 12 to 18 months of age.
Haas H; Richard P; Eymin C; Fiquet A; Kuter B; Soubeyrand B
Hum Vaccin Immunother; 2019; 15(4):778-785. PubMed ID: 30481110
[TBL] [Abstract][Full Text] [Related]
31. [Chickenpox: sufficient reasons for the introduction of vaccination].
Rümke H; de Groot R
Ned Tijdschr Geneeskd; 2006 Dec; 150(48):2630-2. PubMed ID: 17205937
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children.
Shinefield H; Black S; Digilio L; Reisinger K; Blatter M; Gress JO; Brown ML; Eves KA; Klopfer SO; Schödel F; Kuter BJ
Pediatr Infect Dis J; 2005 Aug; 24(8):665-9. PubMed ID: 16094217
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses.
Rümke HC; Loch HP; Hoppenbrouwers K; Vandermeulen C; Malfroot A; Helm K; Douha M; Willems P
Vaccine; 2011 May; 29(22):3842-9. PubMed ID: 21382484
[TBL] [Abstract][Full Text] [Related]
34. Assessing the introduction of universal varicella vaccination in the Netherlands.
Boot HJ; de Melker HE; Stolk EA; de Wit GA; Kimman TG
Vaccine; 2006 Sep; 24(37-39):6288-99. PubMed ID: 16790302
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity and safety of combined measles-mumps-rubella-varicella vaccine using new measles and rubella working seeds in healthy children in Taiwan and Singapore: a phase II, randomized, double-blind trial.
Huang LM; Lee BW; Chan PC; Povey M; Henry O
Hum Vaccin Immunother; 2013 Jun; 9(6):1308-15. PubMed ID: 23425607
[TBL] [Abstract][Full Text] [Related]
36. Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children.
Shinefield H; Black S; Williams WR; Marchant C; Reisinger K; Stewart T; Meissner HC; Guerrero J; Klopfer SO; Xu J; Schödel F; Kuter BJ;
Pediatr Infect Dis J; 2005 Aug; 24(8):670-5. PubMed ID: 16094218
[TBL] [Abstract][Full Text] [Related]
37. Concomitant administration of hepatitis A vaccine with measles/mumps/rubella/varicella and pneumococcal vaccines in healthy 12- to 23-month-old children.
Yetman RJ; Shepard JS; Duke A; Stek JE; Petrecz M; Klopfer SO; Kuter BJ; Schödel FP; Lee AW
Hum Vaccin Immunother; 2013 Aug; 9(8):1691-7. PubMed ID: 23744509
[TBL] [Abstract][Full Text] [Related]
38. Combination measles, mumps, rubella and varicella vaccine.
Arbeter AM; Baker L; Starr SE; Levine BL; Books E; Plotkin SA
Pediatrics; 1986 Oct; 78(4 Pt 2):742-7. PubMed ID: 3763291
[TBL] [Abstract][Full Text] [Related]
39. Influences on immunization rates: Vaccination coverage of mumps, measles, rubella and varicella before and after the STIKO intervention 2011 - A retrospective study.
Sanftenberg L; Schrörs HJ; Schelling J
Vaccine; 2016 Jul; 34(34):3938-41. PubMed ID: 27318420
[TBL] [Abstract][Full Text] [Related]
40. The combination measles, mumps, rubella and varicella vaccine in healthy children.
Arbeter AM; Baker L; Starr SE; Plotkin SA
Dev Biol Stand; 1986; 65():89-93. PubMed ID: 3030864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
